Iodostearic acid in the treatment of advanced gastrointestinal carcinoma.
This phase II non-comparative trial evaluated the efficacy of intramuscular iodostearic acid in the treatment of 30 patients with advanced carcinoma of the gastrointestinal tract. These included 17 patients with colorectal carcinoma, seven with pancreatic carcinoma, four with gastric carcinoma, one with hepatocellular carcinoma and one with cholangiocarcinoma. Iodostearic acid emulsion (2 ml/1.2 g) followed by depomedrone (0.5 ml/10 mg) was injected intramuscularly twice weekly. No serious toxic effects were observed, the main side effects being local pain at the injection site and hot flushes. There were no partial or complete responses. Stable disease was seen in six of 30 patients (20%) at 3 months and three of 30 patients (10%) at 6 months. In conclusion, intramuscular iodostearic acid is relatively non-toxic, however, it appears to be of little value in the treatment of patients with advanced gastrointestinal carcinomas.
Kelly
S B
SB
Department of Surgery, Royal Postgraduate Medical School, Hammersmith Hospital, London, UK.
Cooper
J
J
Llewellyn
S
S
Khoo
D E
DE
Virjee
J
J
Wood
C B
CB
Williamson
R C
RC
Habib
N A
NA
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000556:secondary; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D008875:Middle Aged; D013229:Stearic Acids / Q000627:therapeutic use*; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D013229:Stearic Acids